Companies / Parabilis Medicines, Inc.

Parabilis Medicines, Inc.

Nasdaq: PBLSCIK 1657677CAMBRIDGE, MA

Ownership

121.9M shares outstanding
2.3%Insiders
Ownership
Insiders2.29%2,798,380
10%+ / strategic1.54%1,880,704
Institutions7.50%9,144,845
Public float88.66%108,114,723

% of common shares outstanding (single-class filing figure). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 14

View all →
Insider% of sharesShares
RA Capital Management, L.P.Director · 10% owner
2.17%2,648,278
1.54%1,880,704
0.09%105,414
0.02%30,000
0.01%14,688

Institutional holders 6

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q2 2026
as of
Alphabet Inc.
13F manager
NewCommon Stock$134.65M+4.9M
4,919,498
4.03% of shares
high
Q2 2026
as of
Regeneron Pharmaceuticals, Inc.
13F manager
NewCommon Stock$114.04M+4.2M
4,166,666
3.42% of shares
high
Q2 2026
as of
WINTON GROUP Ltd
13F manager
NewCommon Stock$955.2K+35K
34,900
0.03% of shares
low
Q2 2026
as of
Mitsubishi UFJ Asset Management Co., Ltd.
13F manager
NewCommon Stock$525.5K+19K
19,200
0.02% of shares
low
Q2 2026
as of
Persistent Asset Partners Ltd
13F manager
NewCommon Stock$113.0K+4K
4,130
<0.01% of shares
low
Q2 2026
as of
Bell Investment Advisors, Inc
13F manager
NewCommon Stock$12.3K+451
451
<0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
PBLSCommon StockEquity698955101BBG00KXR8FS7